Kentucky opioid treatment hindered by persistent myths

Some Kentuckians do not start medication-assisted treatment for opioid addiction because of what they think they know. Old ideas about Suboxone, telehealth, and recovery keep them from trying something that works, according to a review of common misconceptions in the state.

Remote opioid treatment and addiction care in the commonwealth has expanded significantly in recent years, but myths persist that stop patients from making the first call. The facts behind seven stubborn myths follow.

Suboxone and the “replacing one addiction” idea

The belief that Suboxone simply swaps one addiction for another is a myth. Buprenorphine, the active ingredient, is a partial agonist with a ceiling effect — higher doses do not produce euphoria. A prescribed dose for a chronic condition is not an addiction. The medication is FDA-approved and has been shown to cut overdose deaths and emergency room visits.

Telehealth is real treatment

A video visit is still a real medical appointment. Research on rural opioid programs found that retention and medication adherence were comparable to in-person care. The same providers, licenses, and prescribing rules apply.

The only difference is the commute.

The old idea that only specialists can prescribe Suboxone came from the X-waiver requirement, but that rule was eliminated. Now any licensed provider can prescribe it, and that change has made treatment more accessible, including via remote care in Kentucky.

A lot of what people think they know about addiction treatment was shaped by policies that no longer exist. The system has moved faster than public perception, and the gap between available care and what people believe is available remains wide in many parts of the state.

Medicaid and remote access

There is a belief that Medicaid patients cannot get treatment started remotely. This myth has roots in a real gap, but it does not reflect current policy. Patients initially started buprenorphine via telehealth at lower rates than others, but that was due to provider participation, not coverage limits. Kentucky Medicaid covers the drug and telehealth, and most plans do not require prior authorization to begin treatment.

Geography is not the main barrier

Geography sounds like an obvious problem, but the real limitation in Eastern Kentucky has been a shortage of providers, not remote care itself. Once a patient has phone or internet access, they can reach the same clinician and medications as someone in a city.

What actually limits access in these areas matters more than distance. Unreliable broadband or cell coverage is a factor. Older patients may be less familiar with video visits. Some local pharmacies do not stock buprenorphine.

But programs work around these gaps. Audio-only visits are allowed when video is not available. Prescriptions go to pharmacies that have supply. Care coordinators or family members can help with technology. The gaps are closing, and treatment is reaching more people.

No required end date

There is a common assumption that medication-assisted treatment only counts if a patient eventually stops. No other chronic condition is held to that standard. Buprenorphine does not come with a required end date. Some people taper off, others stay on it for years because it works. Both are recognized as valid outcomes by addiction medicine.

People often fear that going through a telehealth provider means losing their local pharmacy or doctor. That is not how it works. The pharmacy stays the same. The primary care doctor stays the same. The telehealth provider just adds another layer of support, not a new system.

Each misconception is a reason someone delays getting help they could already access. For Kentuckians looking into remote opioid treatment, a licensed provider like Aegis Medical USA can clarify coverage and treatment before any commitment.